Out of 90 CRC and 8 AA plasma samples, methylated SEPT9 was detected in 30.8% of AA (4/13), 77.8% of stage I (14/18), 85.2% of stage II (23/27), 92.3% of stage III (24/26), 80.0% of stage IV (8/10), and 88.9% of unknown stage (8/9) samples (Table 2 and Figure 2A). Here, SEPTIN9 is linked to colorectal carcinoma.